STOCKHOLM, Jan. 3, 2019 /PRNewswire/ -- IRRAS AB
(Nasdaq First North Premier: IRRAS) today announced that it has
entered into a partnership with HealthLink Europe &
International to serve as IRRAS' global logistics and customer
service partner. Through this partnership, the companies will
provide IRRAS' worldwide customer base with rapid access to the
company's full range of medical products, led by its first
commercial product, IRRAflow®, and industry-leading customer
service support.
Under the terms of the agreement, HealthLink will be responsible
for receiving customer orders, processing customer invoices, and
storing and shipping IRRAS products. With state-of-the-art
facilities in both the United
States and the Netherlands,
HealthLink will enable IRRAS' customers around the world to
seamlessly order and quickly receive their products.
"IRRAS' ability to ship to patients in need around the world has
increased tremendously with our partnership with HealthLink Europe
& International," said Kleanthis G.
Xanthopoulos, Ph.D., President and CEO of IRRAS. "We are
very pleased with our progress thus far with our US launch, which
has already established relationships with several neurocritical
care centers that are currently evaluating IRRAflow, and
this agreement only enhances our ability to support these
customers."
Will Martin, IRRAS' Chief
Commercial Officer added, "This pact allows IRRAS to focus our
resources on product development and commercial execution, while
HealthLink will manage the logistics and ensure that we can rapidly
ship products to any destination around the world. This partnership
is an exciting start to 2019 and we look forward to continuing to
advance our medical device portfolio."
For more information, please contact:
US
Kleanthis G. Xanthopoulos,
Ph.D.
President & CEO
info@irras.com
Europe
Fredrik Alpsten
CFO and Deputy CEO
+46-706-67-31-06
fredrik.alpsten@irras.com
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a
publicly-traded, commercial-stage medical technology company
focused on developing and commercializing innovative solutions for
brain surgery. The company's initial group of products,
IRRAflow®, addresses the complications associated with
the current methods of managing intracranial fluid by using a dual
lumen catheter that combines active irrigation with ongoing fluid
drainage. IRRAflow received FDA clearance in
July 2018.
Regularly during treatment, the IRRAflow catheter is
automatically flushed to prevent common catheter occlusions from
forming. Because IRRAflow is a completely closed
system, it is designed to reduce the documented infection risk
of these procedures. Additionally,
IRRAflow incorporates ICP monitoring and uses a
proprietary software to regulate treatment based on desired
pressure levels.
With its unique product portfolio, protected by property patents
and patent applications, IRRAS is well positioned to establish a
leadership position in the medical device market. IRRAS maintains
its headquarters in Stockholm,
Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com
IRRAS AB (publ) is listed on Nasdaq First North Premier. Wildeco
is certified adviser of the company.
The information was released for public disclosure, through the
agency of the contact person above, on January 3, 2019 at 08.00
a.m. (CET).
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/irras/r/irras-enters-into-global-partnership-with-healthlink-to-support-distributors-of-irras--medical-produ,c2710606
The following files are available for download:
https://mb.cision.com/Main/16550/2710606/971164.pdf
|
Press release
(PDF)
|